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In these times of COVID-19 pandemic, concern has been raised about the potential
effects of SARS-CoV-2 infection on immunocompromised patients, particularly on those
receiving B-cell depleting agents and having therefore a severely depressed humoral
response. Convalescent plasma can be a therapeutic option for these patients.
Understanding the underlying mechanisms of convalescent plasma is crucial to
optimize such therapeutic approach. Here, we describe a COVID-19 patient who was
deeply immunosuppressed following rituximab (anti-CD20 monoclonal antibody) and
concomitant chemotherapy for chronic lymphoid leukemia. His long-term severe T and
B cell lymphopenia allowed to evaluate the treatment effects of convalescent plasma.
Therapeutic outcome was monitored at the clinical, biological and radiological level.
Moreover, anti-SARS-CoV-2 antibody titers (IgM, IgG and IgA) and neutralizing activity
were assessed over time before and after plasma transfusions, alongside to SARS-CoV-2
RNA quantification and virus isolation from the upper respiratory tract. Already after the
first cycle of plasma transfusion, the patient experienced rapid improvement of
pneumonia, inflammation and blood cell counts, which may be related to
the immunomodulatory properties of plasma. Subsequently, the cumulative increase inorg April 2021 | Volume 12 | Article 6135021
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was associated with progressive and finally complete viral clearance, resulting in full clinical
recovery. In this case-report, administration of convalescent plasma revealed a stepwise
effect with an initial and rapid anti-inflammatory activity followed by the progressive SARS-
CoV-2 clearance. These data have potential implications for a more extended use of
convalescent plasma and future monoclonal antibodies in the treatment of
immunosuppressed COVID-19 patients.Keywords: chronic SARS-CoV-2 infection, severe immunosuppression, B-cell depletion, convalescent plasma
therapy, neutralizing antibodies, viral clearanceINTRODUCTION
COVID-19 is a rapidly evolving novel infectious disease caused by
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),
leading to substantial morbidity andmortality. Due to its worldwide
spread, immunocompromised patients, particularly those receiving
B-cell depleting agents and who are unable to mount a specific
humoral response to SARS-CoV2, may be at particular risk for a
severe COVID-19 course (1, 2). In fact, repeated administration of
rituximab (an anti-CD20 monoclonal antibody), is largely applied
in the treatment of various B-cell malignancies and may lead to
prolonged B-cell depletion and impaired production of total
immunoglobulins (Ig) G and IgM (3, 4). Plasma provided by
convalescent donors (i.e. convalescent plasma) has been proposed
as a therapeutic option for COVID-19 (5), based on its partial
effectiveness in other respiratory infections (6, 7). Consistent with
this, several clinical trials have shown a benefit of convalescent
plasma in COVID-19 patients with severe respiratory disease (8–
10). It is likely that high anti-SARS-CoV2 IgG antibody levels (9, 10)
are important for therapeutic effects. However, convalescent plasma
may have additional and currently still unknown mechanisms of
action (11).
This report presents the successful treatment of a severely
immunocompromised patient with prolonged COVID-19 by four
cycles of convalescent plasma transfusion. Our study provides insight
into at least two distinct modes of action of plasma components. The
first one may be related to its proposed anti-inflammatory activity.
The second mechanism is mediated by SARS-CoV-2-specific IgG
and neutralizing antibodies present in convalescent immune plasma,
associated with progressive viral clearance, resulting in full clinical
recovery from infection. Application of convalescent plasma with
relative high titers of anti-SARS-CoV-2 antibodies represents a
promising approach in the context of immunosuppressed patients
with prolonged COVID-19 disease.CASE REPORT
A 74-year-old man, in complete remission of a chronic lymphoid
leukemia (CLL) after 6 cycles of rituximab and bendamustin (last
therapy administrated in December 2019), presented to our
emergency unit on April 1st 2020 with asthenia, loss of weight,
dry cough and diarrhea since a month. He was otherwise healthyorg 2with well-controlled arterial hypertension and type 2 diabetes
mellitus. SARS-CoV-2 RNA was detected (7x106 copies/ml) (12,
13) from a nasopharyngeal swab (defined as day 1). Laboratory
analyses showed a moderate neutropenia, but severe T (114 cell/
mm3) and B (1 cell/mm3) lymphopenia with reduced total
immunoglobulin (Ig) G and IgM levels (Supplementary Figure
1A), while inflammatory markers (C-reactive protein and ferritin)
were elevated (Figure 1A). Chest computed tomography (CT)
revealed bilateral multifocal subpleural and peribronchial ground-
glass opacities typical of COVID-19 pneumonia (14) (Figure 1B
and Supplementary Figure 2). The clinical condition gradually
deteriorated with sub-febrile episodes, persisting dry cough
and diarrhea, and progressive weight loss and cognitive
dysfunction (Figures 1C, D and Supplementary Information).
Inflammatory parameters and blood cell counts remained abnormal
(Figures 1A, E), while persisting SARS-CoV-2 infection was
confirmed (Supplementary Figure 1B). Complementary
investigations excluded other diagnoses (Supplementary
Information). No specific antiviral agents were introduced given
the mild symptoms of COVID-19 (e.g. absence of hypoxemia).
In summary, the patient developed a long-lasting SARS-CoV-2
infection likely related to his severe immunosuppressive status.
Consequently, we hypothesized that convalescent plasma could be
beneficial in this particular case, by providing virus-specific
neutralizing antibodies as well as a potential anti-inflammatory
effect. Plasma units (3x200 ml/donor) were obtained from three
selected donors, who had fully recovered from mild COVID-19
disease (Supplementary Information). Each donor presented
relatively high IgG antibody titers against the S1 (spike)-protein
using Euroimmun ELISA (15) (Supplementary Figure 3A). The
first cycle of ABO-compatible plasma transfusion (two units on two
consecutive days) was given on days 72 and 73 after diagnosis of
SARS-CoV-2 infection, followed by three additional cycles,
administered 10 to 15 days apart (Supplementary Figure 3A).RESULTS
Rapid Improvement of Clinical,
Inflammatory and Radiological Parameters
Following Plasma Transfusion
Within the first eight days after the start of plasma transfusions,
the patient improved clinically, biologically and radiologicallyApril 2021 | Volume 12 | Article 613502
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protein, while absolute platelet counts and hemoglobin levels
showed a more gradual return-to-normal. Follow-up chest CT
scan confirmed a significant improvement in pulmonary
infiltrates (Figure 1B and Supplementary Figure 2). Absolute
lymphocyte counts also substantially improved (Figure 2A), and
largely consisted of increased levels of memory-effector CD4 and
CD8 T cells and of NK cells (by CyTOF multi-parametric mass
cytometry (16); Supplementary Figure 4). Only a moderate rise
was observed for total B cell counts (Figure 2B), mostly
composed of unswitched memory B cells at day 121 (16);
Supplementary Figure 4F), while total IgM and IgG remained
globally stable (Supplementary Figure 1A). These data indicate
clear improvements of inflammation, pneumonia and blood cell
counts , a lready after the 1s t cycle of convalescent
plasma transfusion.Frontiers in Immunology | www.frontiersin.org 3Cumulative Increase in Anti-SARS-CoV-2
IgG Titers Following Successive Plasma
Transfusions
Most patients with COVID-19 develop SARS-CoV-2 IgM and
IgG antibody responses within 19 days after symptom onset (17).
To investigate whether such antibodies were transferred to our
patient following successive cycles of plasma transfusion, we
monitored the anti-SARS-CoV-2 S protein-specific IgG, IgA and
IgM antibody levels by an in-house developed Luminex assay
(18) (Supplementary Information). There was a remarkable
heterogeneity among the three plasma donors, with plasma/
donor 3 exhibiting highest levels of specific antibodies (Figure
2C and Supplementary Figure 3B). Whereas no anti-S IgG
response was detected in the patient’s serum before the start of
plasma transfusion, the antibody titers increased progressively,




FIGURE 1 | Clinical, biological and radiological follow-up before and after plasma transfusions. (A–E), Timeline of chronic SARS-COV-2 infection in a severely
immunosuppressed patient showing inflammatory markers (A), chest CT scan (B), clinical parameters (C), MoCA (Montreal Cognitive Assessment) scores (D), and
complete blood counts (E). (B), Axial slices focused at the level of the apical segment of the right lower lobe. Progressive worsening from multiple ill-defined areas of
ground glass opacities progressing to patchy alveolar consolidation of increasing size. Note the subpleural (blue arrows) and peribronchial (orange arrows)
distribution of the lesions with progressive improvement on post-therapeutic follow-up, alveolar consolidation being replaced by ground glass opacity. (A–E), Arrows
indicate the 4 cycles of plasma transfusion (two units given on two consecutive days of each cycle). The “*” show the three injections of granulocyte-colony
stimulating factor (filgrastim), while “T” indicates the two red blood cell transfusions. Of note, filgrastim injections (< day 40) and red blood cell transfusions did not
result in symptom improvements.April 2021 | Volume 12 | Article 613502
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albeit at much lower levels, was found for anti-S IgA antibodies.
Instead, anti-S IgM antibodies revealed two peaks following
serial plasma transfusions (Figure 2D), again related to the
level of specific-IgM antibodies of each plasma donor, with
plasma/donor 3 showing highest titers (Figure 2C).
Temporal Association Between Detection
of SARS-CoV-2 Neutralizing Antibodies
and Viral Clearance
The activity of neutralizing antibodies was next measured by a
SARS-CoV-2 pseudovirus neutralization assay in all three
plasma as well as in patient’s serum before and after plasma
transfusions (Supplementary Information; Supplementary
Figure 3C). We further observed a boost of SARS-CoV-2Frontiers in Immunology | www.frontiersin.org 4neutralizing activity after each cycle of plasma administration,
in line with the higher antibody activity found in plasma/donor 3
when compared to the two others (Figure 2E). Importantly, this
increase in SARS-CoV-2 neutralizing antibodies (Figure 2E) was
inversely associated to the gradual decline observed in viral loads
in nasopharyngeal swabs (Figure 2F), becoming undetectable for
both E and RdRP genes (13) by day 111 of diagnosis.
To assess whether shedding of infectious SARS-CoV-2 still
occurred after the start of plasma transfusions, we measured the
presence of cultivable SARS-CoV-2 at different time-points (19)
(Supplementary Information). While infectious virus could be
isolated from nasopharyngeal swabs prior and following the 1st
cycle of convalescent plasma transfusion, this was no longer the
case upon the 2nd cycle (Figure 2F). Finally, the patient received




FIGURE 2 | Anti-SARS-CoV-2 antibody and SARS-CoV-2 mRNA follow-up before and after plasma transfusions. (A, B), Timeline showing absolute CD4 and CD8 T
cell counts, including effector-memory subsets and NK cell counts (A), and absolute B cell counts (B). (C, D), Anti-SARS-CoV-2 S protein IgG, IgA and IgM antibody
levels as assessed by an in-house developed Luminex assay for each plasma (C) as well as in the patient’s serum before and following plasma transfusions
(D). (E), Activity of neutralizing antibodies was assessed by a SARS-CoV-2 pseudovirus neutralization assay for each plasma and in patient’s serum at different time-
points. (F), Over-time follow-up of SARS-CoV-2 RNA detection in nasopharyngeal swabs. The cytopathic effect on VeroE6 cells was evaluated after inoculation with
SARS-CoV-2 from nasopharyngeal swabs: C+, successful virus isolation; C-, absence of virus isolation. (A–F), The arrows indicate the 4 cycles of plasma transfusion
(two units given on two consecutive days of each cycle).April 2021 | Volume 12 | Article 613502
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common pathogens, before being discharged from hospital (on
day 115). He was considered as cured after two weeks of
consecutive negative swabs (on day 127), but remaining
potentially vulnerable to SARS-CoV-2 re-infection. The patient
was followed initially by weekly and then monthly outpatient
care. During this period, we observed an initial decline in anti-S
IgG titers (18), followed by their subsequent stabilization over
time (Supplementary Figure 3D). This was coincident to
immune reconstitution, with the normalization of total B cell
counts (Supplementary Figure 3D) and the appearance of naive
B cells (16) (at day 203; Supplementary Figure 4F).DISCUSSION
Collectively, our study offers novel evidence for a clear benefit of
convalescent plasma in this particular case of COVID-19 disease,
with the resolution of clinical, inflammatory and radiological
parameters (Figure 1). Improvement of inflammation,
pneumonia and blood cell counts preceded viral clearance.
Importantly, this patient showed a temporal association
between detection of SARS-CoV-2 neutralizing antibodies and
virus clearance following successive cycles of plasma transfusion
(Figure 2). Thus, our data provide insight into at least two
distinct modes of action of plasma components. The first one is
related to its proposed anti-inflammatory activity, similar to
IVIg, widely used at high-dose for the treatment of several
autoimmune diseases (11, 20). In this line, convalescent plasma
therapy may help in modulating the immune response via F(ab’)
2-dependent mechanisms including blockade of cell-cell
interactions (via cell-surface receptors) and neutralization of
cytokines, complement and autoantibodies (by anti-idiotypic
antibodies). In addition, convalescent plasma activity might
involve Fc-dependent pathways (e.g. modulation of Fcg
receptors on innate immune effector cells and B cells) (11, 20).
A similar rapid anti-inflammatory effect was reported in a series
of 17 consecutive patients with profound B-cell lymphopenia
and prolonged COVID-19 infection, who were treated with 4
units of convalescent plasma (21). Specifically, Hueso and
colleagues (21) observed a decrease in temperature and
inflammatory parameters within a week, associated to oxygen
weaning, while SARS-CoV-2 RNAemia decline occurred later,
between 7 to 14 days after plasma transfusion.
Our observations support a second mechanism of action by
SARS-CoV-2-specific IgG (18) and neutralizing antibodies
present in convalescent immune plasma (Figure 2), which may
mediate direct virus neutralization or other antibody-mediated
pathways (e.g. complement activation, antibody-dependent
cellular cytotoxicity). Passive antibody therapy has the great
advantage to confer immediate immunity to vulnerable
individuals (22). Interestingly, our data further suggest a
relatively rapid effect of convalescent plasma with
disappearance of cultivable SARS-CoV-2 readily after the
second cycle of transfusion, despite intermediate levels of
neutralizing antibodies and high RNA-positivity by qRT-PCRFrontiers in Immunology | www.frontiersin.org 5(Figure 2). This is in line with findings showing that neutralizing
antibodies derived from COVID-19 patients may be effective,
even at concentrations of 9 ng/ml or less (23). Strikingly,
successive cycles of plasma transfusion (every 10-15 days) led
to the cumulative increase in anti-S IgG titers, associated with a
boost of neutralizing antibodies after each administration. Anti-
S-specific IgM titers also followed a kinetic pattern related to the
antibody levels of each transfused donor-plasma unit, indicating
that a de novo endogenous antibody response was improbable at
this stage. These observations are further in agreement with a
recent report showing clinical resolution of COVID-19 following
transfusion of convalescent plasma of high-titer neutralizing
antibodies, in another case of humoral immunodeficiency (24).
Finally, it is certainly possible that CD4 and CD8 T cells played
critical roles (25) in the recovery of this patient who was
primarily B cell deficient. This view is supported by reported
cases of agammaglobulinemia patients who only presented mild
COVID-19 disease (26).CONCLUSION
Convalescent immune plasma therapy revealed stepwise anti-
inflammatory and anti-SARS-CoV-2 effects, resulting in full clinical
recovery from infection in a severely ill immunocompromised
patient. Our data are in line with other studies (21, 24, 27, 28)
reporting symptom resolution and clinical improvement following
passive transfer of anti-SARS-CoV-2 antibodies through convalescent
plasma in patients with immunodeficiency. Together, this therapeutic
option can be considered as safe and represents a promising approach
in the context of immunosuppressed patients with prolonged
COVID-19 disease. At present, it remains to be seen how this
compares to future monoclonal anti-SARS-CoV-2 antibodies and
other novel COVID-19 therapies.DATA AVAILABILITY STATEMENT
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